Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
New England Journal of Medicine · 10.08.2023 · 389 (6) · 514-526
DOI: 10.1056/nejmoa2301972 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 10.08.2023. Verfasst von Ania M Jastreboff und 10 weiteren Autor:innen. Beteiligte Einrichtung: From the Departments of Medicine (Endocrinology and Metabolism) and Pediatrics (Pediatric Endocrinology), Yale University School of Medicine, New Hav…. Hauptthemen laut MEDLINE: Glucagon-Like Peptide 1, Obesity, Gastric Inhibitory Polypeptide, Receptors, Glucagon. Die Arbeit wurde bisher 1192-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: Eli Lilly and Company.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- From the Departments of Medicine (Endocrinology and Metabolism) and Pediatrics (Pediatric Endocrinology), Yale University School of Medicine, New Haven, CT (A.M.J.); the Obesity and Metabolism Institute and Department o…
ORCID-Profile: Ania M Jastreboff, Juan P Frías
Förderung
- Eli Lilly and Company
Zitieren
APA
Jastreboff, A. M., Kaplan, L. M., Frías, J. P., Wu, Q., Du, Y., Gurbuz, S., Coskun, T., Haupt, A., Milicevic, Z., Hartman, M. L., & Retatrutide Phase 2 Obesity Trial Investigators (2023). Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine, 389(6), 514-526. https://doi.org/10.1056/nejmoa2301972
Vancouver
Jastreboff AM, Kaplan LM, Frías JP, Wu Q, Du Y, Gurbuz S, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine. 2023;389(6):514-526. doi:10.1056/nejmoa2301972
BibTeX
@article{Jastreboff2023,
author = {Jastreboff, Ania M and Kaplan, Lee M and Frías, Juan P and Wu, Qiwei and Du, Yu and Gurbuz, Sirel and Coskun, Tamer and Haupt, Axel and Milicevic, Zvonko and Hartman, Mark L and Retatrutide Phase 2 Obesity Trial Investigators, Retatrutide Phase 2 Obesity Trial Investigators},
title = {Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial},
journal = {New England Journal of Medicine},
year = {2023},
volume = {389},
number = {6},
pages = {514--526},
doi = {10.1056/nejmoa2301972}
}
EUVIMED